Cellomics, a business unit within the Fisher Biosciences group, provides complete systems for High Content Screening (HCS) and Analysis (HCA) to drug discovery and systems biology researchers. The Cellomics platform includes automated imaging instrumentation (ArrayScan® and KineticScan® HCS Readers), BioApplication image analysis software, High Content Informatics (HCi™), and HitKit® HCS Reagent Kits, fully integrated to improve the quality and productivity of cell-based assays. Cellomics’ proprietary platforms are in use at multiple sites within the top 15 pharmaceutical companies, as well as leading biotechnology companies and academic centers throughout the world.

• Pittsburgh, PA based company, founded in 1996, a business unit within the Fisher Biosciences group.
  
  
• State-of-art facility integrating research, development, manufacturing, and training
  
  
• Core expertise in:
  • Quantitative Fluorescence Microscopy
  • Cell Biology
  • Molecular Biology
  • Drug Discovery and Pharmacology
  • Engineering
  • Applied Optics and physics
  • Database Design and Data Mining
    
    
• Inventor of High Content Screening and Market Leader in delivering platform solutions
  • Cellomics technology in use at top 15 pharma companies
  • World wide placement in pharma, biopharma, and biotech
  • 4 academic centers with Cellomics technologies established
  • Many multiple unit users

Worldwide Corporate Headquarters:

Cellomics Inc.
100 Technology Drive
Pittsburgh, PA, 15219 USA
Phone: 412-770-2200
Fax: 412-770-2450

European Corporate Headquarters:

Cellomics - Europe
Wyvols Court
Swallowfield Reading
Berkshire
RG7 1WY United Kingdom
Phone: + 44 118 988 0262
Fax: + 44 118 988 0362

 

• Definitions
• Corporate Partnerships